Davita Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Vanguard Information Technology Index Fund ETF trades at $120.86. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | VGT | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | — |
52-Week High | $240.96 | $125.77 |
52-Week Low | $103.87 | $83.59 |
Enterprise Value | $24.44B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
VGT, the Vanguard Information Technology ETF, trades at $121.45, up 1.55% on the day, with a strong bullish technical signal from moving averages. The ETF provides concentrated exposure to major U.S. technology stocks, particularly benefiting from the AI infrastructure build-out. Recent institutional buying activity from firms like Bank of America and Baron Financial Group highlights continued confidence.
The outlook for VGT remains positive, driven by secular tech trends and AI investment, though risks include high concentration in top holdings and sector-specific volatility. The ETF's low-cost structure and pure-play tech focus present a compelling opportunity for long-term growth investors, but its performance is heavily tied to the fortunes of a few mega-cap companies.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →